Cited by 38Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerCancer, Lipids, and Metabolism

TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas

Open access
Maddalena, Francesca, Condelli, Valentina, Matassa, Danilo Swann, Pacelli, Consiglia, Scrima, Rosella, Lettini, Giacomo, Li Bergolis, Valeria, Pietrafesa, Michele +6 more·2020·Molecular Oncology

Abstract

Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic stress. The mechanism by which TRAP1 regulates glycolytic metabolism and the relevance of this regulation in resistance to EGFR inhibitors were investigated in patient‐derived CRC spheres, human CRC cells, samples, and patients. A linear correlation was observed between TRAP1 levels and 18 F‐fluoro‐2‐deoxy‐glucose (18 F‐FDG) uptake upon PET scan or GLUT1 expression in human CRCs. Consistently, TRAP1 enhances GLUT1 expression, glucose uptake, and lactate production and downregulates OXPHOS in CRC patient‐derived spheroids and cell lines. Mechanistically, TRAP1 maximizes lactate production to balance low OXPHOS through the regulation of the glycolytic enzyme phosphofructokinase‐1 (PFK1); this depends on the interaction between TRAP1 and PFK1, which favors PFK1 glycolytic activity and prevents its ubiquitination/degradation. By contrast, TRAP1/PFK1 interaction is lost in conditions of enhanced OXPHOS, which results in loss of TRAP1 regulation of PFK1 activity and lactate production. Notably, TRAP1 regulation of glycolysis is involved in resistance of RAS‐wild‐type CRCs to EGFR monoclonals. Indeed, either TRAP1 upregulation or high glycolytic metabolism impairs cetuximab activity in vitro, whereas TRAP1 targeting and/or inhibition of glycolytic pathway enhances cell response to cetuximab. Finally, a linear correlation between 18 F‐FDG PET uptake and poor response to cetuximab in first‐line therapy in human metastatic CRCs was observed. These results suggest that TRAP1 is a key determinant of CRC metabolic rewiring and favors resistance to EGFR inhibitors through regulation of glycolytic metabolism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.12814

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 54 · Cited by 38

Research works printed but not linked: 1

  1. [31]Berg JM, Tymoczko JL & Stryer L (2002) The glycolytic pathway is tightly controlled, In Biochemistry Section 16.2 (Freeman WH, ed), pp. 668– 676. 5th edn W H Freeman, New York, NY.

Authors
Maddalena, F., Condelli, V., Matassa, D. S., Pacelli, C., Scrima, R., Lettini, G., Li Bergolis, V., Pietrafesa, M., Crispo, F., Piscazzi, A., Storto, G., Capitanio, N., Esposito, F., & Landriscina, M.
Affiliations
  • Centro di Riferimento Oncologico della Basilicata (IT)
  • University of Naples Federico II (IT)
  • University of Foggia (IT)
  • Medical Oncology Unit Department of Medical and Surgical Sciences University of Foggia Italy
Corresponding author
  • Esposito, Franca
  • Landriscina, Matteo
Venue
Molecular Oncology
Publisher
Wiley
Published
2020-10-30
Volume
14
Issue
12
Pages
3030-3047
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W3092512913
Cited by
38
References
54
Citations by year
2025: 7 · 2024: 9 · 2023: 10 · 2022: 6 · 2021: 6
FWCI
1.88
Type
journal article
Language
en
Open access
Locations
  • Molecular Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Associazione Italiana per la Ricerca sul Cancro (IG2015 Id.16738)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
TRAP1, Hsp90 chaperone, Warburg effect, glycolysis, phosphofructokinase-1, oxidative phosphorylation, EGFR inhibitor resistance, cetuximab, colorectal cancer, GLUT1, glucose uptake, lactic acid production, 18F-FDG PET, metabolic reprogramming, patient-derived spheroids, metastatic colorectal cancer
MeSH terms
Cetuximab, Warburg Effect, Oncologic, Endoplasmic Reticulum, Enzyme Stability, Humans, Mitochondria, Oxidation-Reduction, Phenotype, Phosphofructokinase-1, Protein Binding, Colorectal Neoplasms, HSP90 Heat-Shock Proteins, Drug Resistance, Neoplasm, Cell Respiration, Fluorodeoxyglucose F18, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Glucose Transporter Type 1, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review